Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
Multi-target S-DNA increases colorectal cancer screening among previously non-compliant patients

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.04.16
Views: 1753

Dr Barry Berger - Exact Sciences, Madison, USA

Dr Barry Berger speaks with ecancertv at AACR 2016 about response rates to Cologuard, which tests patient stool samples for DNA (S-DNA) indicative of colorectal cancer.

With a high response rate among previously reluctant patients, he describes the benefits to patients and clinicians of a non-invasive test which can also indicate pre-cancerous lesions.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation